Home > Products > Active Pharmaceutical Ingredient (API)

Sinae Active Pharmaceutical Ingredient (API) fabrica, supplementum, Factory

Jiangsu Run'an Pharmaceutical Co, Ltd., subsidiaria omnino possessa de Jiangsu Chiatai Qingjiang Pharmaceutical Co, Ltd., modernus summus tech pharmaceuticus societas specialis in R&D, productionis et venditio fertilitatis ordinandae medicinae et varietatis APIs. Project constructionem mense Novembri 2018 incepit, LIX mu aream obtegens, cum tota obsidione 160 decies Yuan et tota area aedificium 25000 quadratum metrorum.

Praecipua activum medicamentum pharmaceuticum (API) producta: Hydrochloridem Gemcitabinum, Celecoxib, bromhexinum hydrochloridum, Iguratimod, Apremilast, Citrate Tofactinib, Crisaborole, Urapidil Hydrochloride, Sugammadex Natrium, Garlicin, Dexmedetomidine Hydrochloride, Rocuronium Bromidum, Finerenone, etc. elit mundi genus facti et productorum gignentium opificem per constantem emendationem et innovationem in technologiarum, et occasiones praeclarum negotium praebent sodalibus nostris per orbem terrarum. Munus nostrum ad praestantes operas emptores nobis permisit solidas relationes cum sociis nostris toto orbe includere.

View as  
 
Urapidil hydrochloride API

Urapidil hydrochloride API

Urapidil hydrochloride API est ad medicamentum hypertensionis essentialis.

Lege plusMitte Inquisitionem
2-Amino-3,5-dibromo-N-cyclohexyl-N-methylbenzylamine hydrochloride

2-Amino-3,5-dibromo-N-cyclohexyl-N-methylbenzylamine hydrochloride

Seres productum nomen: Bromhexine hydrochloride
Seres aliases: hydrochloride bromhexine; bromhexylamine hydrochloride; benzylcyclohexylamine bromide hydrochloride; 2-amino-3,5-dibromo-N-cyclohexyl-N hydrochloridum methylbenzylamine; N-(2-Amino-3,5-dibromobenzyl)-N-methylcyclohexylamine hydrochloridi;
Anglicus productum nomen: Bromhexine Hydrochloride
Cas#611-75-6

Lege plusMitte Inquisitionem
N-(2-Amino-3,5-dibromobenzyl)-N-methylcyclohexylamine Hydrochloridis

N-(2-Amino-3,5-dibromobenzyl)-N-methylcyclohexylamine Hydrochloridis

Seres productum nomen: Bromhexine hydrochloride
Seres aliases: hydrochloride bromhexine; bromhexylamine hydrochloride; benzylcyclohexylamine bromide hydrochloride; 2-amino-3,5-dibromo-N-cyclohexyl-N hydrochloridum methylbenzylamine; N-(2-Amino-3,5-dibromobenzyl)-N-methylcyclohexylamine hydrochloridi;
Anglicus productum nomen: Bromhexine Hydrochloride
Cas#611-75-6

Lege plusMitte Inquisitionem
CAS NO.611-75-6

CAS NO.611-75-6

Seres productum nomen: Bromhexine hydrochloride
Seres aliases: hydrochloride bromhexine; bromhexylamine hydrochloride; benzylcyclohexylamine bromide hydrochloride; 2-amino-3,5-dibromo-N-cyclohexyl-N hydrochloridum methylbenzylamine; N- (2-Amino-3,5-dibromobenzyl)-N-methylcyclohexylamine hydrochloridi;
Anglicus productum nomen: Bromhexine Hydrochloride
CAS NO.611-75-6

Lege plusMitte Inquisitionem
CAS 611-75-6

CAS 611-75-6

Seres productum nomen: Bromhexine hydrochloride
Seres aliases: hydrochloride bromhexine; bromhexylamine hydrochloride; benzylcyclohexylamine bromide hydrochloride; 2-amino-3,5-dibromo-N-cyclohexyl-N hydrochloridum methylbenzylamine; N- (2-Amino-3,5-dibromobenzyl)-N-methylcyclohexylamine hydrochloridi;
Anglicus productum nomen: Bromhexine Hydrochloride
CAS 611-75-6

Lege plusMitte Inquisitionem
611-75-6

611-75-6

Seres productum nomen: Bromhexine hydrochloride
Seres aliases: hydrochloride bromhexine; bromhexylamine hydrochloride; benzylcyclohexylamine bromide hydrochloride; 2-amino-3,5-dibromo-N-cyclohexyl-N hydrochloridum methylbenzylamine; N- (2-Amino-3,5-dibromobenzyl)-N-methylcyclohexylamine hydrochloridi;
Anglicus productum nomen: Bromhexine Hydrochloride
Cas#611-75-6

Lege plusMitte Inquisitionem
Quiescere potes ex officina nostra emere Active Pharmaceutical Ingredient (API) in Sinis. Pharmaceutical Run'an professionalis Sinarum Active Pharmaceutical Ingredient (API) fabrica et supplementum, qualitas products alta praebere possumus. Grata res emendas ex officina nostra.
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept